These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 28574829)

  • 21. Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC).
    Scalici JM; Arapovic S; Saks EJ; Atkins KA; Petroni G; Duska LR; Slack-Davis JK
    Cancer; 2017 May; 123(6):977-984. PubMed ID: 28263384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stomatin-like protein 2 is overexpressed in epithelial ovarian cancer and predicts poor patient survival.
    Sun F; Ding W; He JH; Wang XJ; Ma ZB; Li YF
    BMC Cancer; 2015 Oct; 15():746. PubMed ID: 26487491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic impact of human leukocyte antigen class I expression and association of platinum resistance with immunologic profiles in epithelial ovarian cancer.
    Mariya T; Hirohashi Y; Torigoe T; Asano T; Kuroda T; Yasuda K; Mizuuchi M; Sonoda T; Saito T; Sato N
    Cancer Immunol Res; 2014 Dec; 2(12):1220-9. PubMed ID: 25324403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-induced expression of EpCAM contributes to therapy resistance in esophageal adenocarcinoma.
    Sun X; Martin RCG; Zheng Q; Farmer R; Pandit H; Li X; Jacob K; Suo J; Li Y
    Cell Oncol (Dordr); 2018 Dec; 41(6):651-662. PubMed ID: 30116994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.
    Gao Y; Shan N; Zhao C; Wang Y; Xu F; Li J; Yu X; Gao L; Yi Z
    Int J Clin Exp Pathol; 2015; 8(5):4923-32. PubMed ID: 26191185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autotaxin Regulates Maintenance of Ovarian Cancer Stem Cells through Lysophosphatidic Acid-Mediated Autocrine Mechanism.
    Seo EJ; Kwon YW; Jang IH; Kim DK; Lee SI; Choi EJ; Kim KH; Suh DS; Lee JH; Choi KU; Lee JW; Mok HJ; Kim KP; Matsumoto H; Aoki J; Kim JH
    Stem Cells; 2016 Mar; 34(3):551-64. PubMed ID: 26800320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
    Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y
    Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of human epididymis protein 4 in chemoresistance and prognosis of epithelial ovarian cancer.
    Lee S; Choi S; Lee Y; Chung D; Hong S; Park N
    J Obstet Gynaecol Res; 2017 Jan; 43(1):220-227. PubMed ID: 27862665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Matrix metalloproteinase-10 regulates stemness of ovarian cancer stem-like cells by activation of canonical Wnt signaling and can be a target of chemotherapy-resistant ovarian cancer.
    Mariya T; Hirohashi Y; Torigoe T; Tabuchi Y; Asano T; Saijo H; Kuroda T; Yasuda K; Mizuuchi M; Saito T; Sato N
    Oncotarget; 2016 May; 7(18):26806-22. PubMed ID: 27072580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.
    Jean S; Li J; Katsaros D; Wubbenhorst B; Maxwell KN; Fishbein L; McLane MW; Benedetto C; Canuto EM; Mitra N; Zhang L; Nathanson KL; Tanyi JL
    Oncotarget; 2016 Jul; 7(30):48577-48585. PubMed ID: 27191893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome.
    Wang YC; Yo YT; Lee HY; Liao YP; Chao TK; Su PH; Lai HC
    Am J Pathol; 2012 Mar; 180(3):1159-1169. PubMed ID: 22222226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
    Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
    Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EpCAM-autoantibody levels in the course of disease of ovarian cancer patients.
    Heubner M; Errico D; Kasimir-Bauer S; Herlyn D; Kimmig R; Wimberger P
    Med Oncol; 2011 Jun; 28(2):626-30. PubMed ID: 20383668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer.
    Ryner L; Guan Y; Firestein R; Xiao Y; Choi Y; Rabe C; Lu S; Fuentes E; Huw LY; Lackner MR; Fu L; Amler LC; Bais C; Wang Y
    Clin Cancer Res; 2015 Jul; 21(13):2941-51. PubMed ID: 25838397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer.
    Marchini S; Fruscio R; Clivio L; Beltrame L; Porcu L; Fuso Nerini I; Cavalieri D; Chiorino G; Cattoretti G; Mangioni C; Milani R; Torri V; Romualdi C; Zambelli A; Romano M; Signorelli M; di Giandomenico S; D'Incalci M
    Eur J Cancer; 2013 Jan; 49(2):520-30. PubMed ID: 22897840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in patients with epithelial ovarian cancer.
    Tas F; Karabulut S; Serilmez M; Ciftci R; Duranyildiz D
    Tumour Biol; 2014 Apr; 35(4):3095-102. PubMed ID: 24307621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NANOG regulates epithelial-mesenchymal transition and chemoresistance in ovarian cancer.
    Qin S; Li Y; Cao X; Du J; Huang X
    Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 27884977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prognostic and predictive value of combined HE4 and CA-125 in ovarian cancer patients.
    Steffensen KD; Waldstrøm M; Brandslund I; Petzold M; Jakobsen A
    Int J Gynecol Cancer; 2012 Nov; 22(9):1474-82. PubMed ID: 23095772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
    Tan DS; Kaye SB
    Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer.
    Paik ES; Sohn I; Baek SY; Shim M; Choi HJ; Kim TJ; Choi CH; Lee JW; Kim BG; Lee YY; Bae DS
    Cancer Res Treat; 2017 Jul; 49(3):635-642. PubMed ID: 27669704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.